TABLE 4.

Predicting Prognosis Via ¹⁸F-FDG PET/CT

Study design	Patients (n)	Median age (y)	Time points	Parameters	Clinical outcome	Cutoff for worse prognosis	Hazard ratio	95% CI	P	Reference
Retrospective study	31	27.5	Baseline, after NCT	SUV_max, TLG	PFS	SUV_max (baseline) > 15	4.514	1.335–15.26	0.015	(51)
						SUV_max (after NCT) > 5	4.527	1.548–13.24	0.006
						TLG % change (10%)	1.096	1.017–1.181	0.016
					OS	SUV_max (after NCT) > 3.3	NR		0.043
						TLG (baseline, per unit)	1.003	1.000–1.005	0.021
Retrospective review	40	15.1	Baseline, after NCT	SUV_max	PFS	SUV_max (after NCT) > 2.5	NR		0.021	(33)
Retrospective study	83	16	Baseline, after NCT	SUV_max, MRV, MTV, TLG	Metastasis-free survival	Baseline MTV (2.0) > 105	3.8	1.5–9.59	0.002	(52)
						Baseline TLG (45%) > 187	2.47	1.056–5.79	0.037
Retrospective study	31	13.9	Baseline, after NCT	SUV_max, SUV_peak, SUV_mean, MTV, TLG, textural features, shape features	PFS	Elongation (baseline) (cutoff NR)	5.583	NR	0.019	(53)
					OS	Elongation (baseline) (cutoff NR)	7.113	NR	0.0062
Retrospective review	34	12.2	Baseline, during NCT, after NCT	SUV_max, SUV_peak, MTV, TLG	Event-free survival	MTV (2.5) (baseline) > 238.06	5.024^*	1.51–16.77	0.01^*	(54)
						TLG (2.5) (baseline) > 981.97	5.740^*	1.34–24.51	0.006^*
						MTV (2.5) (during NCT) > 35.8	8.155^*	1.52–43.69	0.046^*
					OS	MTV (2.5) (baseline) > 238.06	29.447^*	2.21–392.27	0.033^*
						TLG (2.5) (baseline) > 1,022.3	29.447^*	2.21–392.27	0.033^*
						TLG (2.5) (during NCT) > 120.4	34.789^*	2.50–483.84	0.033^*

Retrospective review = retrospective review of prospective study; PFS = progression-free survival; NR = not reported.
↵* Adjusted for histologic response.
Numbers in parentheses indicate segmentation methods to measure MTV and TLG, with (2.0) indicating fixed absolute threshold of SUV 2.0, (2.5) indicating fixed absolute threshold of SUV 2.5, and (45%) indicating fixed relative threshold of 45% of SUV_max.